Background: Endoscopic surveillance for non-dysplastic Barrett's esophagus is
Introduction
Barrett's esophagus is the only known precursor for the development of esophageal adenocarcinoma, an aggressive disease with a poor prognosis [1] . The incidence of esophageal adenocarcinoma has increased dramatically over recent decades in Western countries, with a six fold increase reported over the last 30 years in both the US [2] [3] and Australia [4] . Endoscopic surveillance of Barrett's esophagus is used to identify patients at earlier potentially curable stages, and is in widespread practice and endorsed by several leading bodies in the UK and US [5] [6] despite limited evidence that it confers a survival advantage [7] [8] .
As a cancer prevention strategy, endoscopic surveillance esophagus is controversial because the majority of people with Barrett's esophagus do not develop esophageal cancer and subsequently derive no benefit [9] . The yield of early-stage cancers for patients within a Barrett's surveillance program varies widely from 1/285 to 1/52 patient-years, [10] [11] [12] [13] [14] [15] or 0.2% to 2% per year [1] . However, advocates of surveillance suggest it is the only option available for early detection, and since adenocarcinoma occurs through a known sequence of metaplastic-dysplastic states, detecting these various pre-cancerous states within a surveillance program is critical [6] .
Numerous studies were published during 1999-2009 but produced conflicting results about the value of surveillance, and are now largely outdated as they were based on poor quality evidence [16] . Clinical practice has also improved notably with lower mortality rates reported for esophagectomy and greater use of less invasive endoscopic techniques. Some of the previous studies showed surveillance is not cost-effective under any scenario tested [17] [18] , while others concluded that surveillance is economically acceptable under certain conditions (for example, when the surveillance interval is lengthened [19] [20] ). Hampering this work has been a lack of evidence for crucial inputs for modeling (e.g., quality of life, proportion of patients progressing among dysplasia grades). Moreover, analyses have not adequately scrutinized the clinical uncertainty of alternative management options for early stage esophageal cancer [16] such as endoscopic procedures, which are less expensive and less invasive than oesophagectomy, yet may be equally effective [16, 21] .
Mortality rates for oesophagectomy also appear to be improving, particularly in specialist centers, while epidemiological studies have produced more rigorous estimates of the natural history of Barrett's esophagus [22] .
Identifying high-risk factors and targeting surveillance to high-risk individuals might extend to them the benefits of surveillance, while at the same time avoiding potentially unnecessary hospital resource use associated with surveillance in lowrisk individuals. At present stratifying risk is difficult and has not entered clinical practice, although earlier studies have suggested this might be possible, and much current research is evaluating potential biomarkers which might be used for this purpose. In the future, if useful biomarkers can be identified, then predictive biomarker testing might allow the identification of patients who are more likely to progress to cancer, and this information could be used to target these individuals for closer surveillance, whilst at the same time excluding patients who are at low risk.
This might then allow surveillance recommendations to be tailored to risk, and could improve cost-effectiveness. To date clinically useful biomarkers which enable this type of approach to be developed remain unproven. However, past work has shown a combination of critical abnormalities within the tumor-suppressor genes TP53 and CDKN2A, as well as DNA content abnormalities (tetraploidy and aneuploidy), are associated with a high risk of progression to esophageal adenocarcinoma [23] . It is therefore reasonable to propose that biomarker testing of BE is a foreseeable development in clinical care. While the precise components of future tests are not known at this stage, the likely costs and benefits can be estimated and included in models to predict their likely overall impact [24] .
To evaluate these issues further, this study assessed the cost-effectiveness of endoscopic surveillance for non-dysplastic Barrett's esophagus within a structured program based on accepted international guidelines. Updated epidemiological data and observational study findings were used for the present modeled analysis, as new evidence provides a more reliable basis for determining surveillance outcomes, costs, and for the natural history of cancer progression. In addition, the model was modified to evaluate the effect of adding a hypothetical biomarker test as a way of identifying patients at higher-risk of developing esophageal cancer. Whilst the latter approach remains untested in clinical practice, the considerable current effort to identify predictive biomarkers for Barrett's esophagus suggests that such markers will at some stage be advocated for clinical practice, this strategy should also be evaluated for cost-effectiveness before becoming routine.
Methods

Description of Strategies
Three strategies were modeled: 1) no surveillance; 2) endoscopic surveillance alone; and 3) endoscopic surveillance modified by a hypothetical biomarker test (see below). Endoscopic surveillance intervals were based on UK British Society of Gastroenterology guidelines; 2-yearly for non-dysplastic Barrett's esophagus with intestinal metaplasia, and 6-monthly for Barrett's esophagus with low-grade dysplasia [25] . It was assumed that appropriate scheduling of endoscopies was achieved, mucosal biopsies were collected using the Seattle protocol (i.e. 4-quadrant biopsies at 2cm intervals with histopathology checked by two pathologists if high grade dysplasia was identified) [26] , diagnoses of Barrett's esophagus or dysplasia were accurate, and all patients attended their scheduled appointments. The data used to determine the clinical outcomes was derived from a database which underpins a managed Barrett's esophagus surveillance program in Adelaide, Australia, in which there was a greater than 90% compliance with all of the above assumptions [26] .
Markov Model
A health state transition Markov Model was constructed in TreeAge Pro 2011 (TreeAge Software Inc, Williamstown, MA, USA) and designed to synthesize published evidence and data from the primary patient-level dataset. A two-stage approach was taken where clinical pathways and treatments following a diagnosis of esophageal adenocarcinoma were first analyzed (the 'treatment model') [27] and then integrated within a larger surveillance model focusing on the parameters pertaining to surveillance activities (the 'surveillance model') ( Treatments for high-grade dysplasia or esophageal adenocarcinoma were constructed with particular attention to different clinical algorithms for T1a and T1b tumors, inclusion of post-operative mortality, inclusion of less-invasive endoscopic treatments (endoscopic mucosal resection and radiofrequency ablation) and validated structurally by clinicians [27] . Individuals who remained alive after five years following a diagnosis of high-grade dysplasia or esophageal adenocarcinoma received on-going endoscopy every six months for three years and annually thereafter. These individuals were assumed to die eventually of other causes.
Individuals may die of any cause at any time during the model from any health state based on Australian age-dependent mortality tables [29] , weighted by a higher proportion of men (66%) commonly observed for patients with Barrett's esophagus.
Data Inputs and Sources
Transition probabilities
Pivotal to the model are the progression rates from non-dysplastic Barrett's esophagus to adenocarcinoma, and low-grade dysplasia to adenocarcinoma, creating the model's health state transition probabilities. A literature search was undertaken to extract the most recent and relevant data estimates (Table 1) . Large observational studies provided data on the progression rates reflecting the natural history of Barrett's esophagus [22, 28, 30] . For the progression from non-dysplastic Barrett's esophagus to adenocarcinoma, the estimate of 0.33% per year was selected from a meta-analysis by Desai et al. 2011 on a subset of higher-quality studies. This pooled estimate excluded studies capturing prevalent cases of adenocarcinoma and high-grade dysplasia and included those with greater than five years follow-up [31] . This estimate was also very similar to those presented in recent large observational studies in Northern Ireland 0.27% [28] , The Netherlands 0.39% [30] , but somewhat higher than reported by Hvid-Jensen et al. 2011, 0.12% (95%CI: 0.09%, 0.15%), although this latter study included patients with columnar epithelium without intestinal metaplasia [22] . We tested the results using estimates 0.09% and 0.5% in a sensitivity analysis. We assessed the literature reporting corresponding progression rates for patients within a surveillance program with a focus on more recent studies ( Table 2 ). Our estimates were taken from a prospective dataset kept by the authors at Flinders Medical Centre, Adelaide (South Australia) because this involved a relatively high number of patients and patient years of followup (2040), with confirmed intestinal metaplasia with any length of BE (Supplementary File). Patients also had high adherence to appointments and were followed within a well-managed surveillance program compliant with UK recommendations [26, 32] ( Table 2 ). Under surveillance, the TreeAge model was calibrated using an implementation of the Markov model in Microsoft Excel run over a 9-year period and 2040 patient-years. The progression rates were iteratively derived from reversemodel runs, starting with estimates derived from the surveillance data. The derived rates accurately reproduced the incidences and cumulative incidences of low-and high-grade dysplasia and esophageal adenocarcinoma and gastro-esophageal junction carcinoma observed in the surveillance program. The rates and cumulative incidences were then verified in the TreeAge model.
Utilities
The background utility value for the Australian population has recently been reported at 0.895 [33] (with 1.0 representing best possible health) using the EQ-5D instrument and Australian quality-of-life preferences. Disutilities for the model health states were calculated as the difference between 0.895 and utilities reported in the literature relating to esophageal cancer health states [34] [35] [36] [37] , in most instances measured by the EQ-5D (with UK preferences) ( Table 1 ). It was assumed that patients with nondysplastic Barrett's esophagus and low-grade dysplasia would be asymptomatic as a consequence of using proton pump inhibitor agents to control symptoms, and therefore have no disutility from the background norm.
Resource Use and Costs
The study took an Australian health system perspective and all costs (Table 1) Proton pump inhibitor medications were assumed to be taken by all individuals and were not included in the model as costs were not expected to differ across the intervention strategies. Resources were valued using national price schedules and public hospital clinical costs for inpatient surgical stays. The mean cost of an oesophagectomy included in-hospital adverse events and intensive care unit admissions for some patients. We assumed total costs for esophageal cancer, separated by T stage, occurred during the first 12 months after diagnosis.
Analyses
The mean costs and QALYs were generated using an expected (mean per person) value analysis. For each strategy, this reflects the aggregated probabilities and values assigned to alternative pathways. Costs and benefits were discounted at 5% per year to adjust for the relative value of present costs and life years. The incremental cost-effectiveness ratios (ICER) were calculated using the 'no surveillance' strategy as the reference. One-way sensitivity analyses were undertaken where each parameter was varied through a range of plausible values (Table 1 ) and changes to the base results were observed. We varied the surveillance frequency (3-or 5-yearly for non-dysplastic Barrett's, annual for low-grade dysplasia), the starting age (55 years, 60 years), the maximum surveillance duration (5, 10, 20 years) and the discount rate (0%, 1.5%, 3.5%). All other model parameters were tested between high and low values (Table 1) using the 95% confidence intervals where available, values reported in the literature, or ± 20%. We also considered the cost impact on the results when we increased the proportion of patients with T1a cancers receiving endoscopic treatments instead of oesophagectomy (to 90%, from a base case of 50%). Sensitivity analyses were not performed on other variables relating to the treatment of high-grade dysplasia or esophageal cancer (e.g., esophageal mortality rates, utility values for cancer stage, costs of chemoradiation); these were comprehensively undertaken in previously published analyses [27] and will have negligible effect on a surveillance population because they affect a small proportion of individuals. A probabilistic sensitivity analysis was also performed by re-sampling 5000 times at random from assigned probability distributions for each parameter to address the uncertainty of data estimates simultaneously. Gamma distributions were used for costs and beta distributions were used for probabilities and utility scores. To aid interpretation, a cost-effectiveness threshold of US$100,000 per QALY was used [39] .
Modification of model using a hypothetical biomarker strategy
In addition to the standard surveillance model, we modified and re-evaluated the Barrett's esophagus surveillance program using a hypothetical biomarker test. The 'surveillance with biomarker' strategy parameters was based on the procedures, methods, and outcomes reported by Galipeau et al. (2007) [23] . In this study, patients with Barrett's esophagus were evaluated at baseline for TP53 and CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing, loss of heterozygosity, methylation-specific PCR and flow cytometry. Their patient cohort was typical for gender, age, and Barrett's esophagus segment length, compared to other specialty referral centers. The cumulative esophageal adenocarcinoma incidence and relative risk of progression to esophageal adenocarcinoma at 10 years were calculated for patients with different numbers of the positive markers at baseline, relative to patients with no abnormalities. For our model we took the data from this study and used it to estimate the risk of progression for individuals with a "positive biomarker test". A positive test was determined to be the presence of three of the abnormalities identified by Galipeau et al. In Galipeau et al's study these patients had a significantly higher cancer incidence over 10 years follow-up [23] . The diagnostic performance of the biomarker tests for predicting the progression from BE, low-or high-grade dysplasia to esophageal cancer was 40.7% sensitivity and 98.0% specificity. These performance figures would be considered the lowest acceptable bound for a clinical test and therefore represent the most conservative scenario in our model. Under our model, patients with the "positive biomarker test" were assigned to receive more frequent (6-monthly) endoscopic surveillance. Transition rates were derived by iterating a hidden Markov model (see below) using an expectation-maximization algorithm to generate overall expected rates of progression (proportionally adjusted to be relative to our overall base rates) to cancer and dysplasia for positive or negative tests [40] . Alternative strategies were also examined where: 1) patients with a "positive biomarker test" received prompt radiofrequency ablation therapy and accrued the same outcomes as patients with high-grade dysplasia, and patients with a "negative biomarker test" received no further surveillance; and 2) patients testing negative received no surveillance for the first five years and 2-yearly surveillance thereafter. Table 3 ). The incremental cost per QALY was improved for surveillance modified by a biomarker test due to lower costs and similar QALYs, than surveillance alone, arising from a higher proportion of low-risk individuals with a negative test result receiving no further surveillance. In a comparison of 'no surveillance' versus patients testing positive for biomarkers and receiving radiofrequency ablation or no surveillance for those testing negative, the results showed that 'no surveillance' was superior with higher QALYs and fewer total costs. However, if patients testing positive for biomarkers received 6-monthly surveillance while patients with negative tests received no surveillance in the first five years and 2-yearly surveillance thereafter, the ICER was $48,111.
Results
Over
Results of the sensitivity analyses indicated the findings were sensitive to several estimates ( Table 4 ). The most sensitive estimates were the annual progression rates from non-dysplastic Barrett's esophagus to high-grade dysplasia, and from low-to high-grade dysplasia, with high progression rates under surveillance leading to high cost-effectiveness ratios. Low progression estimates for all non-surveillance states also increased the cost-effectiveness ratios substantially. The hypothetical increased yield of high-grade dysplasia found with positive biomarker tests and subsequent changes in management also influenced the ratios markedly (Table 4) . Less frequent surveillance endoscopies improved the cost-effectiveness of surveillance substantially. When a disutility was incorporated for individuals undergoing surveillance, the 'no surveillance' option was superior to surveillance alone but surveillance with a biomarker remained cost-effective. Finally, the results of the twoway sensitivity analyses show surveillance with hypothetical biomarkers would be preferred at current estimates of progression from non-dysplastic Barrett's esophagus to low-or high-grade dysplasia, under no surveillance and lower proportions of individuals with positive biomarkers (Figure 2a) . The biomarker surveillance option would also be preferred under current progression estimates and higher background utility values (Figure 2b ) or younger surveillance starting age (<55 years) (Figure 2c ).
For the surveillance with a hypothetical biomarker test versus no surveillance, more favorable cost-effectiveness ratios were found in virtually all sensitivity analyses but relied on the base assumption of estimates of progression across dysplasia states and adenocarcinoma. In the probabilistic sensitivity analysis, using 5000 simulations, the probability that surveillance alone was cost-effective compared with no surveillance was 16.0%, while the probability was 60.6% for surveillance with a biomarker testing strategy (Figure 3) , at the threshold of $100,000 per QALY gained.
Discussion
The cost-effectiveness of surveillance for patients with non-dysplastic Barrett's esophagus compared to no surveillance has been under close scrutiny [41] [42] .
Although Markov modeling has limitations that include relying on assumptions and simplifications that may not reflect the full clinical profile of presenting individuals, it is probably not feasible to do large multicenter trials on surveillance using 'detected cancers' as the primary outcome due to the low numbers of cases expected, long recruitment time and the high participant numbers needed. Markov modeling is therefore an alternative approach that can provide useful information to map the predicted long-term outcomes and costs of a Barrett's esophagus surveillance program.
Our results indicated that the surveillance alone strategy, as presented here, is unlikely to be cost-effective, when compared with no surveillance. This result is uncertain, however, due to the volatility in the model that results from small variations in the progression rates between dysplasia grades and the subsequent development of adenocarcinoma. However, the cost-effectiveness was markedly improved under the hypothetical scenario of biomarker testing, with acceptable limits of sensitivity and specificity, which serves to differentiate surveillance program participants into low-and high-risk groups, and subsequently with more targeted treatment pathways and higher proportions of pre-or early-stage cancers detected.
The cost-effectiveness of an alternative biomarker strategy remained favorable if patients testing negative for biomarkers did not receive surveillance in the first five years and received 2-yearly surveillance thereafter. In addition, if surveillance of patients with non-dysplastic Barrett's esophagus were scheduled less frequently, either 3-or 5-yearly and/or annually for low-grade dysplasia, the cost-effectiveness of surveillance would be acceptable in most health systems. This, however, assumes that no cancers are missed or progress to advanced stage disease and there is only limited evidence to support this, especially for low-grade dysplasia [43] .
Our findings contrast those from the most recent cost-effectiveness study on Barrett's esophagus surveillance reported by Roberts KJ et al. in the UK (2011). This study involved 654 patient years of surveillance and concluded that Barrett's esophagus surveillance was cost-effective. Unlike our study, their study was not a Markov model but a more simple and short-term analysis of a surveillance population using a subset of prevalent cases as the comparator. They did not perform sensitivity analyses. Several other Markov modeling studies using 'no surveillance' comparators have concluded the additional gains during surveillance are not costeffective [17] [18] 35] . Compared to our findings, the favorable cost-effectiveness ratios previously found [19] [20] 44] are likely to be due to a combination of the use of very high utility values (~0.97), infrequent surveillance intervals (5 yearly) and less coverage of the costs involved. These studies also used higher rates of progression to cancer under surveillance (~0.50%). In effect, the most favorable estimates were In so much that cost-effectiveness was clearly improved, our study suggests that endoscopic surveillance should be limited to high-risk individuals. However, identifying these high risk individuals is currently difficult and there are no biomarker based strategies currently available for routine clinical practice. Nevertheless, if future work can identify a strategy, this might have the desired impact of lowering health care costs and increasing QALYs, provided the increased surveillance of positive-testing individuals increases the capture of adenocarcinomas using similar estimates to those used here. Biomarker testing also presents an opportunity for objective assessment of risk, and could replace risk assessment based on the identification of low-grade dysplasia and the problems with variation in observer and histopathology interpretation for this diagnosis. However, the appropriateness of biomarker testing, its efficacy within a surveillance program, its feasibility and its acceptance are yet to be determined. Further research involving patients with positive biomarkers and additional high-risk factors such as, being male, the presence of esophagitis, length of Barrett's esophagus and length of time with Barrett's esophagus [28] is warranted on economic and efficacy grounds to elicit outcomes from a more targeted high-risk surveillance population.
The extent to which these findings are transferable to other settings will depend on several factors. The costs used in our study are specific for Australia. However, their relativities to each other will be broadly similar across similar Western Countries. The assumptions made regarding the surveillance program were based on an established long-running program with well-managed and clearly audited follow-up procedures to ensure patient adherence to appointments and endoscopist adherence to standardized protocols [26] . Additionally, endoscopic surveillance methods are not always consistent [45] [46] , and a reproducible diagnosis of Barrett's esophagus, with or without dysplasia, can also be difficult in individuals with short segments and hiatus hernia [47] [48] [49] . A limitation of our analysis is that we did not test our base results against different compliance rates with surveillance scheduling.
Although the 90% compliance rate may be higher than that achieved in other parts of the world, our results still showed 'surveillance alone' had a low probability of being cost-effective. Surveillance is likely to be less cost effective if a lower compliance is modeled. Finally, although the UK-based British Society of Gastroenterology guidelines do not require patients to have confirmed IM, our sample only included patients with IM and therefore, the results are likely to be applicable to patients undergoing surveillance in the US and other countries which define BE as requiring the presence of IM.
While we have based our treatment costs on a thorough analysis of treatment patterns among a large cohort [38] , we have not considered the various treatment options for Barrett's esophagus which overlap with those for treating symptomatic gastro-esophageal reflux disease, namely proton pump inhibitor medications versus anti-reflux surgery. The goal of these treatments has been to treat reflux symptoms, with a hope that this might to limit progression or prevent cancer by altering the natural history of Barrett's esophagus. However, neither form of anti-reflux therapy produces predictable regression, or prevents cancer development [50] [51] , so for the purpose of developing this model we assumed everyone was managed with proton pump inhibitor medication. We did not model the treatment of radiofrequency ablation for low-grade dysplasia as this is still an area of controversy, and there is no consensus that these patients should undergo radiofrequency ablation. There is also a lack of outcome data for radiofrequency ablation for low-grade dysplasia to allow this approach to be incorporated into our model. If this was included, however,, it is certain that the costs of the surveillance arms would have been higher than our base results due to the cost of radiofrequency ablation treatment added to ongoing endoscopic surveillance. Cost effectiveness for radiofrequency ablation for low-grade dysplasia can only be achieved if patients undergoing ablation can be discharged from ongoing follow-up, and there is currently no evidence to support this.
Our study enhances previous attempts to assess the cost-effectiveness of a Barrett's surveillance program for several reasons. First, we used a two-stage modeling approach, building in a detailed cancer treatment model within our surveillance model to elucidate the current drivers of cost/health outcomes of various available cancer treatments [27] . It was important to discern what features of treatment are likely to impact on costs/outcomes to ensure that when patients undergoing surveillance were identified with high-grade dysplasia or adenocarcinoma, potential cost-efficiencies of surveillance would not be jeopardized by expensive treatment options. In our model, a proportion of patients with high-grade dysplasia were promptly and actively 'treated' rather than using watchful waiting, which reflects current clinical practice. We also explored the potential for risk stratification and the effect this might have on the cost-effectiveness of surveillance. In addition, we used current and updated epidemiological estimates of cancer progression from large observational cohort studies (primary patient-level and published data) both involving general population Barrett's registries and long-term single-center surveillance program audit reports. Using population-based published estimates on progression rates and quality-of-life enhances the previous economic evaluations that were largely reliant on author assumptions [16] .
Calls have been made around the world to consider the cost-effectiveness of appropriate management strategies for patients with Barrett's esophagus. Using current estimates of the malignant potential of Barrett's esophagus in the wider population versus those reported in surveillance program audits, surveillance of all patients with non-dysplastic Barrett's esophagus may not be cost-effective. However, further work to identify high-risk individuals, perhaps in the future using a biomarker based strategy, might enable endoscopy surveillance to be tailored to high-risk individuals and thereby improve the economic acceptability of endoscopy based surveillance of Barrett's esophagus. Rates were converted to 6-monthly probabilities using a rate to probability formula: and also adjusted for the diminishing pool of persons in the model over time 2. Rates were derived by iterating the model backwards to generate overall expected rates of progression to EAC and HGD for BM+ and BM-in our surveillance program -these rates were derived from Galipeau et al's published data for p53 LOH + aneuploidy + tetraploidy, and proportionally adjusted to be relative to our overall base rates. 3. Similar to a health-related quality of life score from 0-1 with 1=highest health status 4. Treatment costs were originally calculated over approx. 5 years with the majority occurring in the first year, therefore these were assumed to accrue during the first 12 months in the model. 5. Radiofrequency ablation costs do not include estimate of infrastructure costs, which would include the base Radiofrequency ablation machine. LGD to HGD low -2.76%
LGD to HGD high -4.15% Negative NDBE to HGD low -0.16% NDBE to HGD high -0.24% NDBE to LGD low -1.2% NDBE to LGD high -1.8%
LGD to HGD low -0.37%
LGD to HGD high -0.56% n/a same as base n/a same as base ACO: adenocarcinoma of the esophagus, HGD: high-grade dysplasia, LGD: low-grade dysplasia, NDBE: non-dysplastic Barrett's esophagus, 1. Dominated means the no surveillance strategy produced lower costs and higher QALYs than either surveillance option. 2. This also simultaneously decreases the corresponding rates of progression in the biomarker negative testing arm. 
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